Roshchino

Researchers are evaluating the efficacy and safety of cariprazine in treating schizophrenia among adolescents aged 13 to 17 years. This international, multicenter study is designed as a randomized, double-blind, placebo-controlled trial to understand how cariprazine affects symptoms of schizophrenia in this younger population. Participants will be randomly assigned to receive either cariprazine capsules at doses of 1.5 mg or 4.5 mg once daily, or matching placebo capsules once daily. The treatment phase lasts for six weeks, during which participants take the assigned capsules orally every day. During the study, participants will be monitored regularly to assess changes in their schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also evaluate safety and tolerability throughout the trial. The main measurement is the change in PANSS total score from the start to the end of the six-week period. The study is designed to last until December 2026.

This research aims to evaluate whether the study drug DMB-I INN Latrepirdine can improve cognitive functions in adults with Alzheimer type dementia and to assess its safety. The study also compares DMB-I to a placebo to understand its effects better, including when taken long-term. It involves patients aged 60 to 90 years diagnosed with mild to moderate Alzheimers type dementia. The study is a multicenter, randomized, double-blind, placebo-controlled trial with two treatment stages lasting 26 weeks each. In Stage 1, participants are assigned to one of three groups DMB-I alone, DMB-I plus Akatinol Memantine4, or placebo plus Akatinol Memantine4. After Stage 1, all groups continue for another 26 weeks in an open-label phase where some treatments may change. The total study duration per participant is about 56 weeks including screening and follow-up periods. Participants will visit the clinic 13 times for checkups and tests, and keep a diary of their symptoms. Researchers will measure changes in cognitive function using the ADAS-Cog scale at multiple time points up to week 52, comparing scores to baseline. Safety and long-term effects of DMB-I will also be monitored. Follow-up visits occur after treatment to assess ongoing health and outcomes.